AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

5,601.00p
   
  • Change Today:
    -8.00p
  • 52 Week High: 6,107.00
  • 52 Week Low: 4,705.00
  • Currency: UK Pounds
  • Shares Issued: 1,266.78m
  • Volume: 805,772
  • Market Cap: 70,952m
  • RiskGrade: 83
  • Beta: 0.00

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 3.8% 3.8%
Div Cover 1.5 1.2
Op Mrgn 18.2% 23.0%
ROCE 465.6%  
Latest F'cast
P/E 17.2 22.1
PEG n/a n/a
Pr/Revenue 4.6 4.1
Pr/Book 5.6  
Latest F'cast
Revenue -5.5% -35.2%
PBT -37.3% 34.8%
EPS -0.7% -22.5%
DPS n/a -41.6%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-13 25,711.00 3,267.00 505.00¢ 9.3 n/a -26% 280.00¢ 6.0%
31-Dec-14 26,095.00 1,246.00 428.00¢ 14.0 n/a -15% 280.00¢ 4.7%
31-Dec-15 23,641.00 3,069.00 426.00¢ 14.3 n/a -0% 280.00¢ 4.6%
31-Dec-16 21,319.00 3,552.00 431.00¢ 13.5 13.5 +1% 280.00¢ 4.8%
31-Dec-17 20,152.00 2,227.00 428.00¢ 15.7 n/a -1% 280.00¢ 4.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-18 17,168.43 3,948.12 253.78p 22.1 n/a -22% 215.16p 3.8%
31-Dec-19 18,379.81 4,331.35 290.58p 19.3 1.3 +14% 217.30p 3.8%

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

FDA approves AZ's Lumoxiti in hairy cell leukaemia 14-Sep-2018 07:00 RNS
Tezepelumab FDA Breakthrough Therapy Designation 07-Sep-2018 07:00 RNS
Directorate Change 06-Sep-2018 07:00 RNS

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 5,601.00p
Change Today -8.00p
% Change -0.14 %
52 Week High 6,107.00
52 Week Low 4,705.00
Volume 805,772
Shares Issued 1,266.78m
Market Cap 70,952m
Beta 0.00
RiskGrade 83

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
1.1% below the market average1.1% below the market average1.1% below the market average1.1% below the market average1.1% below the market average
81.25% above the sector average81.25% above the sector average81.25% above the sector average81.25% above the sector average81.25% above the sector average
Price Trend
63.73% above the market average63.73% above the market average63.73% above the market average63.73% above the market average63.73% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average
Income
38.83% above the market average38.83% above the market average38.83% above the market average38.83% above the market average38.83% above the market average
84.62% above the sector average84.62% above the sector average84.62% above the sector average84.62% above the sector average84.62% above the sector average
Growth
84.31% below the market average84.31% below the market average84.31% below the market average84.31% below the market average84.31% below the market average
90.48% below the sector average90.48% below the sector average90.48% below the sector average90.48% below the sector average90.48% below the sector average

What The Brokers Say

Strong Buy 17
Buy 1
Neutral 7
Sell 1
Strong Sell 4
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 09-Aug-18 15-Feb-18
Paid 10-Sep-18 19-Mar-18
Amount 90.00¢ 190.00¢

Trades for 19-Sep-2018

Time Volume / Share Price
15:53 90 @ 5,601.00p
15:53 110 @ 5,601.00p
15:53 1 @ 5,600.00p
15:53 5 @ 5,599.00p
15:53 109 @ 5,599.00p

Top of Page